| Project/Area Number |
17591445
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
NAITO Zenya Nippon Medical School, Graduate School of Medicine, Professor, 大学院・医学研究科, 教授 (20237184)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIWATA Toshiyuki Nippon Medical School, Faculty of Medicine, Associate Professor, 医学部, 助教授 (90203041)
KUDO Mitsuhiro Nippon Medical School, Faculty of Medicine, Research Associate, 医学部, 助手 (20256978)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2006: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | pancreatic cancer / pancreatitis / lumican / cell growth / proteoglycan / immunohistochemistry / 膵臓癌 |
|---|
| Research Abstract |
Lumican is a member of a small leucine-rich proteoglycan family and its overexpression has been reported in breast, colorectal, uterine cervical and pancreatic cancers. The expression of lumican in stromal tissues in breast cancer is associated with a high tumor grade, a low estrogen receptor expression level, and young age. Lumican expression in the cytoplasm in advanced colorectal cancer correlated with poor prognosis. Lumican expression was previously reported in pancreatic cancer and adjacent stromal tissues. Reverse-transcription polymerase chain reaction (RT-PCR) and Western blot analyses revealed lumican mRNA and protein expression in six pancreatic ductal adenocarcinoma (PDAC) cell lines (PANC-1, MIA PaCa-2, KLM-1, Capan-1, PK-1 and PK-8). On the basis of its immunoreactivity, lumican was found to be localized in islet cells of normal pancreatic tissues. In pancreatic cancer tissues, lumican was localized in the cytoplasm of cancer cells in 30 of 53 (57%) cancer patients, whereas lumican was detected in stromal tissues in 36 of 53 (68%) cancer patients. Lumican expression in pancreatic cancer cells did not correlate with clinicopathological factors, whereas lumican expression in stromal tissues correlated with the female gender, advanced stage, retroperitoneal and duodenal invasion. Patients with lumican-positive stromal tissues survived shorter than those with lumican-negative stromal tissues. These results suggest that lumican in stromal tissues play important roles in the growth and invasion of pancreatic cancer. Different glycosylated side chains of lumican may present in cytoplasm of cancer cells and adjacent stromal tissues.
|
